Impact of chronic graft- versus-host disease on non-relapse mortality and survival

Leuk Lymphoma. 2024 Nov;65(11):1698-1705. doi: 10.1080/10428194.2024.2365910. Epub 2024 Jun 12.

Abstract

Chronic graft-versus-host-disease (cGVHD) is one of the primary causes of morbidity and mortality for patients who undergo allogeneic hematopoietic stem cell transplantation (allo-HCT). In recent years, advancements in allo-HCT have allowed a broader range of patients to receive transplant, particularly older patients. We sought to assess the impact of cGVHD on outcomes in patients undergoing allo-HCT, for older patients as compared to their counterparts. We performed a retrospective analysis of all patients who underwent allo-HCT 1999-2018. Our results showed that those patients who developed cGVHD by D + 180 had an increased risk and incidence of NRM as compared to those patients without cGVHD. There was no significant difference in outcomes for those patients with cGVHD by age (≥60 years old [yo] and <60 yo). These findings suggest the significant morbidity of cGVHD, regardless of age.

Keywords: Chronic GVHD; allogeneic stem cell transplant; non-relapse mortality.

MeSH terms

  • Adolescent
  • Adult
  • Age Factors
  • Aged
  • Chronic Disease
  • Female
  • Graft vs Host Disease* / diagnosis
  • Graft vs Host Disease* / etiology
  • Graft vs Host Disease* / mortality
  • Hematologic Neoplasms / mortality
  • Hematologic Neoplasms / therapy
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Hematopoietic Stem Cell Transplantation* / mortality
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Prognosis
  • Retrospective Studies
  • Risk Factors
  • Transplantation Conditioning / adverse effects
  • Transplantation Conditioning / methods
  • Transplantation, Homologous
  • Young Adult